FDA Clears the Focus Diagnostics Simplexa™ Flu A/B & RSV Direct Test
News Dec 10, 2014
As the 2014-2015 flu season begins, Focus Diagnostics has announced that its Simplexa™ Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.
The FDA, which granted 510(k) clearance to the test kit originally in July 2012, cleared additional analytical reactivity to include Flu A H7N9 and H3N2v, among other strains, based on studies that demonstrated the test's analytical performance.
"Influenza viruses constantly evolve, and virus subtypes can quickly develop and infect large populations. It is vital that the tests can detect the recently circulating and geographically diverse strains," said Hollis (Holly) J. Batterman, MD, medical director, infectious diseases, Focus Diagnostics.
"The studies we've performed with our Simplexa Influenza/RSV assay reflect our commitment to making sure health care providers have access to molecular infectious disease tests that are highly robust and use the most innovative technologies. We are particularly gratified that we can offer testing for recently circulating influenza viruses before this year's flu season is in full swing," added Dr. Batterman.
Seasonal influenza epidemics occur primarily during the winter in temperate climates and year round in tropical climates. According to the Centers for Disease Control and Prevention (CDC), flu activity most commonly peaks in the United States between December and February.
The Simplexa Flu A/B & RSV Direct kit on the 3M Integrated Cycler is a real-time RT-PCR molecular test that was 510(k) cleared by the FDA in July 2012 for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors.
Simplexa Flu A/B & RSV Direct was one of the first to be FDA cleared for molecular detection of influenza A, B and respiratory syncytial virus. The performance characteristics of the test with clinical specimens that are positive for novel avian influenza have not been established.
The test kit with the eight additional strains is now available directly in the United States and internationally through the global distribution network of Focus Diagnostics. Classified as CLIA moderate complexity, the test can report results in about an hour through a proprietary process that eliminates nucleic acid extraction, a time consuming technique typically employed by molecular tests.
Influenza viruses constantly change, causing the regular appearance of novel strains. The additional eight strains for which FDA cleared analytical reactivity are: H7N9, H3N2 (both the Minnesota and Indiana strains) as well as H1N1 (2011), H3N2 (the Ohio and Texas strains) and influenza B (Brisbane and Wisconsin strains).
Of particular concern are the novel avian influenza A strain H7N9, which can cause death in as many as one third of infected patients, and the H3N2v, which infects humans more easily than other swine influenza virus, according to the CDC.
"Timely diagnosis is critical to effective management of infectious diseases like influenza. By providing fast, reliable results in about an hour, our Simplexa platform helps physicians quickly diagnose and treat patients," said Michelle Tabb, PhD, vice president of research and development for Focus Diagnostics. "These changes to our Simplexa test reflect our vision to develop high quality molecular tests that deliver critical insights to improve outcomes and empower better health."
Influenza occurs globally, affecting an estimated 5%-10% of adults and 20%-30% of children, according to the World Health Organization.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.